Rapid health technology assessment of rituximab in the treatment of idiopathic membranous nephropathy
DUAN Yin-yin
ZHANG Liu
QIN Hai-yan
WU Xiao-li
Abstract：Objective:To evaluate the efficacy,safety,and economy of rituximab(RTX)in the treatment of idiopathic membranous nephropathy(IMN)through rapid health technology assessment(HTA),and to provide evidence for decision makers.Methods:Retrieve databases such as PubMed,Cochrane Library,Wanfang,and CNKI,as well as relevant HTA websites and databases were searched.Two researchers independently selected literature,extracted data,and evaluated the quality based on inclusion and exclusion criteria,and then conducted qualitative analysis of the results.Results:Fourteen papers in systematic evaluation/Meta analysis and 3 papers in pharmacoeconomics research were included.In terms of effectiveness,rituximab had certain advantages in increasing clinical remission rate,blood albumin level,glomerular filtration rate,and reducing urinary protein,blood creatinine,and recurrence rate.In terms of safety,the incidence of adverse reactions in RTX was low and the symptoms were mild.In terms of economy,although the cost of single dose RTX was relatively high,as the willingness to pay threshold(WTP)increased,RTX had a more cost-effective advantage.Conclusion:RTX treatment for IMN has good efficacy and safety,and is a medium to long-term and economically effective treatment method.
Keywords：RituximabIdiopathic membranous nephropathyRapid health technology assessment
Publication Date：2023-12-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 462-466 )